Seite - 45 - in Cancer Nanotheranostics - What Have We Learnd So Far?

Dawidczyket al. Nanomedicines for cancer therapy Hubert, A., Lyass, O., Pode, D., and Gabizon, A. (2000). Doxil (Caelyx): an exploratory studywithpharmacokinetics inpatientswithhormone-refractory prostate cancer. Anticancer Drugs 11, 123–127. doi: 10.1097/00001813- 200002000-00009 Huynh,N. T., Roger, E., Lautram,N., Benoit, J. P., andPassirani, C. (2010). The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting.Nanomedicine(Lond).5,1415–1433.doi:10.2217/nnm.10.113 Hynes,R.O.(2002).Integrins:bidirectional,allostericsignalingmachines.Cell110, 673–687.doi:10.1016/S0092-8674(02)00971-6 Immordino,M.L.,Dosio,F., andCattel,L. (2006).Stealth liposomes: reviewof the basic science, rationale, and clinical applications, existing andpotential. Int. J. Nanomedicine1,297–315. Iyer, A. K., Su, Y., Feng, J., Lan, X., Zhu, X., Liu, Y., et al. (2011). The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoidmesothelioma. Biomaterials 32, 2605–2613. doi: 10.1016/j.biomaterials.2010.11.073 Jacquet, J.M.,Bressolle,F.,Galtier,M.,Bourrier,M.,Donadio,D., Jourdan, J., etal. (1990).Doxorubicin anddoxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters. Cancer Chemother. Pharmacol. 27, 219–225. doi:10.1007/BF00685716 Jain, K. K. (2012). Advances in use of functionalized carbon nanotubes for drug design and discovery. Expert Opin. Drug Discov. 7, 1029–1037. doi: 10.1517/17460441.2012.722078 Jain, R. K. (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.Science307,58–62.doi:10.1126/science.1104819 Jain,R.K.,andStylianopoulos,T.(2010).Deliveringnanomedicinetosolidtumors. Nat.Rev.Clin.Oncol.7,653–664.doi:10.1038/nrclinonc.2010.139 Jones, C. H., Chen, C. K., Ravikrishnan, A., Rane, S., and Pfeifer, B. A. (2013). Overcoming nonviral gene delivery barriers: perspective and future. Mol. Pharm.10,4082–4098.doi:10.1021/mp400467x Kamen, B. A., and Smith, A. K. (2004). A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell mod- els in vitro. Adv. Drug Deliv. Rev. 56, 1085–1097. doi: 10.1016/j.addr.2004. 01.002 Kawano,K.,Watanabe,M.,Yamamoto,T., Yokoyama,M.,Opanasopit, P.,Okano, T., et al. (2006). Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles. J. Control. Release 112, 329–332. doi: 10.1016/j.jconrel.2006.03.012 Keefe,A.D., Pai, S., andEllington,A. (2010).Aptamers as therapeutics.Nat.Rev. DrugDiscov.9,537–550.doi:10.1038/nrd3141 Kheirolomoom, A., Mahakian, L. M., Lai, C. Y., Lindfors, H. A., Seo, J. W., Paoli, E. E., et al. (2010). Copper-doxorubicin as a nanoparticle cargo retains efficacy with minimal toxicity. Mol. Pharm. 7, 1948–1958. doi: 10.1021/ mp100245u Khemtong, C., Kessinger, C. W., Ren, J., Bey, E. A., Yang, S. G., Guthi, J. S., et al. (2009). In vivo off-resonance saturation magnetic resonance imag- ing of alphavbeta3-targeted superparamagnetic nanoparticles.Cancer Res. 69, 1651–1658.doi:10.1158/0008-5472.CAN-08-3231 Kim, S. H., Jeong, J. H., Lee, S. H., Kim, S. W., and Park, T. G. (2008). Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatmentof cancer. J.Control. Release129, 107–116. doi: 10.1016/j.jconrel.2008.03.008 Knop,K.,Hoogenboom,R., Fischer,D., andSchubert,U. S. (2010).Poly(ethylene glycol) indrugdelivery: pros and cons aswell as potential alternatives.Angew. Chem. Int.Ed.Engl. 49,6288–6308.doi:10.1002/anie.200902672 Kresse, M., Wagner, S., Pfefferer, D., Lawaczeck, R., Elste, V., and Semmler, W. (1998). Targeting of ultrasmall superparamagnetic iron oxide (USPIO) parti- cles to tumorcells invivobyusing transferrin receptorpathways.Magn.Reson. Med.40,236–242.doi:10.1002/mrm.1910400209 Krogh-Madsen, M., Bender, B., Jensen, M. K., Nielsen, O. J., Friberg, L. E., andHonore, P.H. (2012). Populationpharmacokinetics of cytarabine, etopo- side, and daunorubicin in the treatment for acutemyeloid leukemia.Cancer Chemother.Pharmacol.69,1155–1163.doi:10.1007/s00280-011-1800-z Kumar,M.,Yigit,M.,Dai,G.P.,Moore,A.,andMedarova,Z.(2010).Image-guided breast tumor therapyusing a small interferingRNAnanodrug.CancerRes.70, 7553–7561.doi:10.1158/0008-5472.CAN-10-2070 Kunjachan,S.,Pola,R.,Gremse,F.,Theek,B.,Ehling, J.,Moeckel,D., et al. (2014). PassiveversusactivetumortargetingusingRGD-andNGR-modifiedpolymeric nanomedicines.NanoLett.14,972–981.doi:10.1021/nl404391r Lasic,D.D.,Frederik,P.M.,Stuart,M.C.,Barenholz,Y.,andMcIntosh,T.J.(1992). Gelation of liposome interior. A novelmethod for drug encapsulation. FEBS Lett.312,255–258.doi:10.1016/0014-5793(92)80947-F Le Garrec, D., Taillefer, J., Van Lier, J. E., Lenaerts, V., and Leroux, J. C. (2002). Optimizing pH-responsive polymeric micelles for drug delivery in a cancer photodynamic therapy model. J. Drug Target. 10, 429–437. doi: 10.1080/1061186021000001887 Libutti, S. K., Paciotti, G. F., Byrnes, A. A., Alexander, H. R., Gannon, W. E., Walker,M., et al. (2010). Phase I and Pharmacokinetic Studies of CYT-6091, aNovel PEGylatedColloidalGold-rhTNFNanomedicine.Clin.CancerRes.16, 6139–6149.doi:10.1158/1078-0432.CCR-10-0978 Liechty, W. B., and Peppas, N. A. (2012). Expert opinion: responsive polymer nanoparticles in cancer therapy. Eur. J. Pharm. Biopharm. 80, 241–246. doi: 10.1016/j.ejpb.2011.08.004 Liu, X. W., Tao, H. Q., Yang, K., Zhang, S. A., Lee, S. T., and Liu, Z. A. (2011).Optimizationof surface chemistry on single-walled carbonnanotubes for in vivo photothermal ablation of tumors. Biomaterials 32, 144–151. doi: 10.1016/j.biomaterials.2010.08.096 Lorusso, P.M.,Weiss,D.,Guardino, E.,Girish, S., and Sliwkowski,M.X. (2011). Trastuzumabemtansine:auniqueantibody-drugconjugate indevelopment for humanepidermalgrowthfactorreceptor2-positivecancer.Clin.CancerRes.17, 6437–6447.doi:10.1158/1078-0432.CCR-11-0762 Lowis, S., Lewis, I., Elsworth, A.,Weston, C., Doz, F., Vassal, G., et al. (2006). A phase I studyof intravenous liposomal daunorubicin (DaunoXome) inpaedi- atricpatientswithrelapsedorresistantsolidtumours.Br.J.Cancer95,571–580. doi:10.1038/sj.bjc.6603288 Lu,D.,Burris,H.A.,Wang,B.,Dees,E.C.,Cortes, J., Joshi,A., et al. (2012).Drug interactionpotential of trastuzumab emtansine (T-DM1) combinedwithper- tuzumab in patients withHER2-positivemetastatic breast cancer.Curr. Drug Metab.13,911–922.doi:10.2174/138920012802138688 Lu,W., Xiong, C., Zhang, G., Huang, Q., Zhang, R., Zhang, J. Z., et al. (2009). Targeted photothermal ablation of murine melanomas with melanocyte- stimulatinghormoneanalog-conjugatedhollowgoldnanospheres.Clin.Cancer Res.15,876–886.doi:10.1158/1078-0432.CCR-08-1480 Lu, W., Zhang, G., Zhang, R., Flores, L. G., Huang, Q., Gelovani, J. G., et al. (2010).Tumorsite-specificsilencingofNF-kappaBp65bytargetedhollowgold nanosphere-mediated photothermal transfection.Cancer Res. 70, 3177–3188. doi:10.1158/0008-5472.CAN-09-3379 Lupold, S. E., Hicke, B. J., Lin, Y., and Coffey, D. S. (2002). Identification and characterization of nuclease-stabilized RNAmolecules that bind human prostate cancer cells via the prostate-specificmembrane antigen.Cancer Res. 62,4029–4033.doi:10.1158/0008-5472.Can-12-2152 Lyass,O.,Uziely, B., Ben-Yosef, R., Tzemach,D.,Heshing,N. I., Lotem,M., et al. (2000). Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin(Doxil) inmetastaticbreastcarcinoma.Cancer89,1037–1047.doi: 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z Mahakian,L.M.,Farwell,D.G.,Zhang,H.,Seo,J.W.,Poirier,B.,Tinling,S.P.,etal. (2014).ComparisonofPETImagingwithCu-64-LiposomesandF-18-FDGin the 7,12-Dimethylbenz[a]anthracene (DMBA)-inducedhamster buccal pouch model of oral dysplasia and squamous cell carcinoma.Mol. Imaging Biol. 16, 284–292.doi:10.1007/s11307-013-0676-1 Medintz, I. L.,Uyeda,H.T.,Goldman,E.R., andMattoussi,H. (2005).Quantum dot bioconjugates for imaging, labelling and sensing.Nat.Mater. 4, 435–446. doi:10.1038/nmat1390 Melancon,M.P.,Lu,W.,Yang,Z.,Zhang,R.,Cheng,Z.,Elliot,A.M., etal. (2008). In vitro and in vivo targeting of hollow gold nanoshells directed at epidermal growth factor receptor forphotothermal ablation therapy.Mol.CancerTher.7, 1730–1739.doi:10.1158/1535-7163.MCT-08-0016 Michalet, X., Pinaud, F. F., Bentolila, L. A., Tsay, J. M., Doose, S., Li, J. J., et al. (2005). Quantumdots for live cells, in vivo imaging, and diagnostics. Science 307,538–544.doi:10.1126/science.1104274 Miele, E., Spinelli, G. P., Miele, E., Tomao, F., and Tomao, S. (2009). Albumin- boundformulationofpaclitaxel (AbraxaneABI-007) in the treatmentofbreast cancer. Int. J.Nanomedicine4,99–105. Miller, T., Breyer, S., Van Colen, G.,Mier,W., Haberkorn, U., Geissler, S., et al. (2013). Premature drug release of polymericmicelles and its effects on tumor targeting. Int. J.Pharm.445,117–124.doi:10.1016/j.ijpharm.2013.01.059 Mintzer,M.A.,andSimanek,E.E.(2009).Nonviralvectorsforgenedelivery.Chem. Rev.109,259–302.doi:10.1021/cr800409e www.frontiersin.org August2014 |Volume2 |Article69 | 45